BioPharma Reporter
NOVEMBER 21, 2022
Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.
pharmaphorum
FEBRUARY 3, 2022
There is a rising demand for vaccines, insulin, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 12, 2023
Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.
Camargo
OCTOBER 14, 2020
Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The FDA has also recently launched the Software Pre-Certification Pilot Program to provide an efficient regulatory framework for developers of SaMD products.
XTalks
SEPTEMBER 23, 2020
Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.
XTalks
FEBRUARY 24, 2021
The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.
pharmaphorum
JULY 27, 2021
Drug delivery specialist Aptar Group has agreed a deal to take a near two-thirds share in Voluntis, a French developer of digital therapeutics (DTx), with a view to taking full control of the company later this year. per share in the initial deal, which will give it a 64.6% stake in the company.
Expert insights. Personalized for you.
98 
Let's personalize your content